Table 1.
Baseline patient characteristics and laboratory findings in total cohort, and survivors vs. non-survivors.
| Variable | Septic cohort*, n = 101 | Survivors, n = 82 | Non-survivors, n = 19 | p-Value |
|---|---|---|---|---|
| GENDER, AGE | ||||
| Male, n (%) | 55 (55) | 43 (52) | 12 (63) | 0.452 |
| Age, median (range) | 64 (23–89) | 64 (23–89) | 64 (45–86) | 0.449 |
| SEVERITY OF DISEASE, MEAN ± SD | ||||
| SOFA 0 h | 10 ± 3.4 | 9.6 ± 3.2 | 11.6 ± 4.1 | 0.054 |
| SOFA 24 h | 8.9 ± 3.7 | 8.3 ± 3.6 | 11.7 ± 2.8 | 0.0004 |
| SOFA 96 h | 5.2 ± 3.9 | 5.2 ± 3.5 | 5.4 ± 5.5 | 0.767 |
| APACHE II | 22.7 ± 8.0 | 21.0 ± 7.4 | 26.7 ± 9.8 | 0.016 |
| ACQUISITION OF INFECTION, n (%) | ||||
| Community | 62 (61) | 51 (62) | 11 (58) | 0.796 |
| Hospital | 39 (39) | 31 (38) | 8 (42) | 0.796 |
| UNDERLYING CONDITIONS, n (%) | ||||
| Previously healthy, n (%) | 11 (11) | 9 (11) | 2 (11) | 1.0 |
| Diabetes | 16 (16) | 13 (16) | 3 (16) | 1.0 |
| Smoking | 15 (15) | 10 (12) | 5 (42) | 0.151 |
| Alcohol abuse | 11 (11) | 7 (9) | 4 (21) | 0.212 |
| History of cancer | 31 (31) | 22 (27) | 9 (47) | 0.100 |
| Immunosuppressiona | 27 (27) | 19 (23) | 8 (42) | 0.146 |
| Hypertension | 24 (24) | 23 (28) | 1 (5) | 0.038 |
| Heart diseaseb | 21 (21) | 17 (21) | 4 (21) | 1.0 |
| Pulmonaryc | 3 (3) | 3 (4) | 0 (0) | 0.573 |
| Liver diseased | 8 (4) | 4 (5) | 4 (21) | 0.039 |
| Neurologic diseasee | 5 (5) | 3 (4) | 2 (11) | 0.236 |
| Renal failure | 4 (4) | 3 (4) | 1 (5) | 0.572 |
| Other diseasesf | 15 (15) | 12 (15) | 3 (16) | 1.0 |
| Blood cultures (n = 92) | 76 | 16 | ||
| Confirmed positive (%) | 50 (54) | 40 (53) | 10 (63) | 0.585 |
| CLINICAL MANIFESTATIONS, n (%) | ||||
| Pneumonia | 25 (28) | 17 (21) | 8 (80) | 0.075 |
| Urinary tract infection | 16 (16) | 14 (17) | 2 (10) | 0.729 |
| Intra-abdominal infection | 42 (42) | 36 (44) | 6 (60) | 0.440 |
| Skin/soft tissue infection | 9 (9) | 7 (9) | 2 (10) | 0.676 |
| Neutropenia | 4 (4) | 3 (4) | 1 (5) | 0.572 |
| Bacterial meningitis | 3 (3) | 3 (4) | 0 (0) | 1.0 |
| Undefined origin | 2 (2) | 2 (2) | 0 (0) | 1.0 |
| LABORATORY FINDINGS, MEDIAN (IQR) | ||||
| C-reactive protein (mg/L) | 226 (140–308) | 227 (143–316) | 210 (89–276) | 0.224 |
| WBC (109/L) | 14.3 (5.6–23.7) | 14.3 (5.9–21.9) | 13.6 (0.9–27.2) | 0.664 |
| Hemoglobin (g/L) | 105 (92.5–117.5) | 104.5 (96.5–118) | 106 (99–113) | 0.651 |
| Platelet count (109) | 165 (82–265) | 171.5 (83–266) | 126 (66–213) | 0.262 |
| P-glucose (mmol/L) | 7.0 (6.1–8.9) | 7.1 (6.4–9.0) | 6.4 (4.5–7.3) | 0.031 |
| aPTT (s) | 46 (40.5–56) | 45.5 (40–53.3) | 52 (44–62) | 0.082 |
| Creatinine (μmol/L) | 155 (89–246.5) | 153 (86–250) | 163 (108–225) | 0.357 |
| Bilirubin (μmol/L) | 18 (9–30.5) | 16 (8–30) | 23 (15–54) | 0.058 |
| INR | 1.4 (1.2–1.8) | 1.4 (1.2–1.7) | 1.6 (1.2–2.7) | 0.043 |
| D-dimer (mg/L) | 1.9 (0.8–3.9) | 1.5 (0.8–3.7) | 3.3 (1.4–7.2) | 0.063 |
| Lactate (mmol/L) | 3.2 (2.2–5.2) | 3 (2.1–4.0) | 7.6 (2.8–11.1) | 0.004 |
*Septic cohort consisted of 86 patients with septic shock and 15 patients with severe sepsis.
a According to APACHE II criteria.
b A history of heart disease contains of coronary artery disease and congestive heart failure.
c Chronic obstructive pulmonary disease or emphysema or asthma.
d Liver disease contains of hepatitis with or without cirrhosis and primary biliary cirrhosis.
e Neurologic diseases: previous stroke and multiple sclerosis.
f Inflammatory bowel disease, rheumatoid arthritis, psychiatric disease, ventricular ulcer, or hypothyreos.